Search

Search Constraints

You searched for: Author/Creator Kotsianidis, Ioannis

Search Results

3. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. (August 2018)

4. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. Issue 3 (23rd February 2022)

5. Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry. (6th November 2022)

7. Cover Image. Issue 2 (13th April 2021)

8. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. (January 2021)

9. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Issue 1 (January 2020)